Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM).
Autor: | Grumann C; Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Hermann Staudinger Graduate School, University of Freiburg, Freiburg, Germany., Huppertz LM; Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Bisel P; Institute for Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany., Angerer V; Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Forensic Toxicology, Institute of Forensic Medicine, St. Gallen, Switzerland., Auwärter V; Institute of Forensic Medicine, Forensic Toxicology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. |
---|---|
Jazyk: | angličtina |
Zdroj: | Drug testing and analysis [Drug Test Anal] 2019 Jul; Vol. 11 (7), pp. 1009-1017. Date of Electronic Publication: 2019 Mar 20. |
DOI: | 10.1002/dta.2577 |
Abstrakt: | Pharmaceutical research not only provides the basis for the development of new medicinal products but also for the synthesis of new drugs of abuse. 3-Fluorophenmetrazine (3-FPM), a fluorinated derivative of the anorectic phenmetrazine, was first patented in 2011 and appeared on the drug market in 2014. Though invented for potential medical purposes, pharmacokinetic data on this compound, crucial for interpreting forensic as well as clinical cases, are not available. Therefore, a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method for the detection of 3-FPM in serum, urine, and oral fluid was developed, validated for urine and serum, and used to quantify 3-FPM in samples obtained during a controlled self-experiment. The method proved to be linear, selective and sufficiently sensitive. The limits of detection (LODs) were 0.1 ng/mL, 0.2 ng/mL, and 0.05 ng/mL in serum, urine, and oral fluid. Inter-day precision and intra-day precision (RSD) in serum samples were below 6.3% and below 8.5%, respectively. The highest serum concentration (c (© 2019 John Wiley & Sons, Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |